New Technologies, Treatments Can End Opioid Use

Posted on 30 October 2018 by James Carroll

Those suffering from America’s opioid crisis recently received two major messages of hope.

On Oct. 24, President Donald Trump signed the Opioid Crisis Response Act (OCRA) into law. Dozens of bills designed to address the diverse aspects of the opioid crisis were consolidated into one strategic and integrated approach.

OCRA received overwhelming bi-partisan support in both Chambers.

HR6, which is now Public Law 115-2716, broke new ground in being the first legislation to mandate aggressive development and adoption of alternative pain treatments that include “innovative medical technologies for pain management.”

On Oct. 11, Congress held its first ever briefing on ending opioid use through “innovative medical technologies for pain management.”

Photobiomodulation (PBM) was the featured technology.

Read the full news story on newsmax.com

Posted in Industry, THE FUTURE OF PBM/LLLT | on New Technologies, Treatments Can End Opioid Use

THOR CEO leads official US Congressional Briefing on Photobiomodulation (PBM)

Posted on 28 October 2018 by Ian

Washington DC, 11th October, 2018. James Carroll (CEO, THOR Photomedicine), Prof. Praveen Arany (University at Buffalo, NY), Annette Quinn RN (Program Manager, Radiation Oncology, University of Pittsburgh (UPMC) Cancer Center) introduced Photobiomodulation (PBM) to a large gathering of senior policy officials at the Rayburn House Office Building.

James Carroll presented evidence to Congress on the effectiveness of PBM for treating pain and where it can be used in place of opioids. Prof. Praveen Arany explained how and why it works, and Annette Quinn RN gave her first hand experience in treating over 854 patients with Oral Mucositis.

The briefing was a historic step for PBM, moving the conversation forward as members of congress were shown stories by members of the public on how PBM had impacted them and enabled them to live a life free from opioids.

The panel outlined the needs for PBM adoption as

  1. Research grants to fund further basic science experiments, therapeutic dose, and large multicenter clinical trials.
  2. FDA to create a PBM specific product code.
  3. Public and private health insurance reimbursement.

For further information on this event visit www.CongressPBM.com

Posted in Industry, THE FUTURE OF PBM/LLLT | on THOR CEO leads official US Congressional Briefing on Photobiomodulation (PBM)

LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

Posted on 24 October 2018 by James Carroll

LumiThera's Valeda® Light Delivery SystemLumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Optos Plc, a division of Nikon, Inc., Japan to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care. The announcement follows the recent CE Mark Certification for the European Union (EU) for the treatment of dry AMD utilizing LumiThera’s Valeda™ Light Delivery System.

“The Distribution agreement with Optos allows LumiThera to begin commercialization throughout Europe and establishes a collaboration with a partner in the retinal imaging area,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “Optos is a global leader in ultra-widefield retinal imaging technologies and we are honored to be working with them to open up a new age in the treatment of AMD.”

“Optos is pleased to add the Valeda™ Light Delivery System to our product range and to further support eye care professionals to diagnose and manage retinal diseases. This arrangement allows our customers to visualize AMD in the far periphery with color and autofluorescence ultra-widefield retinal imaging and provide a PBM treatment for dry AMD. This is very important for the patients who have this complicated, degenerative disease,” stated Robert Kennedy, Chief Executive Officer, Optos.

LumiThera recently sponsored a symposium on PBM in ocular disease and presented final data from the LIGHTSITE I study at the Euretina conference in September 2018 and has a multi-center trial in Europe planned to begin in the near term to further support clinical, anatomical, and patient benefits with the Valeda™ Light Delivery System. The therapy consists of a series of light-based treatments to the retinal cells, resulting in improved energy production and addressing inflammation, ischemia and metabolic dysfunction that contribute to the disease.

View the press release on Lumithera website at www.lumithera.com

Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.

Posted in Industry | on LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

Testimonial: Dr. Darren Bell

Posted on 17 October 2018 by Ian

Dr. Darren Bell“I love THOR. The product is great. The seminar was very informative and helpful. And the post-purchase support with Mark and the research assistant has been nothing short of exceptional. I feel like I definitely made the right decision by choosing to purchase a THOR Laser. Thanks.”

Dr. Darren Bell
Chiropractor
New York, USA

View current photobiomodulation therapy training dates in your location.

Posted in Testimonials | on Testimonial: Dr. Darren Bell

Course Testimonial: Iva Stamatova

Posted on 8 October 2018 by Ian

Iva Stamatova, Dentist“The course was excellent, stimulating and profound. James Carroll’s presentation was highly inspirational and covered very thoroughly all clinical applications of cold lasers supported by robust clinical evidence. I’m truly motivated that PBM could be broadly used in dentistry; its availability may contribute to faster healing, better pain management and perhaps risk reduction of some common oral diseases. Many thanks for the great day spent with Thor laser.”

Iva Stamatova
Dentist
Hull, UK

View current photobiomodulation therapy training dates in your location.

Posted in Testimonials | on Course Testimonial: Iva Stamatova

Testimonial: Annie Blain

Posted on 1 October 2018 by Ian

Annie Blain, Dental Hygienist“Thank you for your excellent course. We bought the THOR laser and use it all week!”

Annie Blain
Dental Hygienist
Montreal, Canada

View current photobiomodulation therapy training dates in your location.

Posted in Testimonials | on Testimonial: Annie Blain

NovoTHOR testimonial: Phoenix Suns

Posted on 21 September 2018 by Ian

Aaron Nelson, Athletic Care/Head Athletic Trainer of Phoenix Suns explains why their players are using the NovoTHOR. He says the NovoTHOR is a very interesting piece of equipment for performance, recovery and speeding up the healing process throughout the whole body.

More NovoTHOR Testimonials | NovoTHOR Treatment Locations

View current photobiomodulation therapy training dates in your location.

Disclaimer: These comments by healthcare professionals and their patients are solely their own. They are uncompensated personal stories about how they have used, or been impacted by, light therapy. These uses have not been reviewed or cleared by FDA.

Posted in Testimonials, Video of the Week | on NovoTHOR testimonial: Phoenix Suns